Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Prostate Cancer Metastatic × olaparib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Ovarian Neoplasms 30 Breast Neoplasms 22 Prostatic Neoplasms 15 Triple Negative Breast Neoplasms 14 Fallopian Tube Neoplasms 10 Neoplasms 7 Glioma 6 Endometrial Neoplasms 6 Carcinoma, Ovarian Epithelial 6 Stomach Neoplasms 5 Small Cell Lung Carcinoma 5 Pancreatic Neoplasms 5 Cholangiocarcinoma 5 Urinary Bladder Neoplasms 4 Sarcoma 4 Lymphoma, Non-Hodgkin 4 Fanconi Anemia, Complementation Group D1 4 Carcinoma, Non-Small-Cell Lung 4 Advanced Breast Cancer 4 Uterine Cervical Neoplasms 3 Squamous Cell Carcinoma of Head and Neck 3 Osteosarcoma 3 Medulloblastoma 3 Lung Neoplasms 3 Colorectal Neoplasms 3 Wilms Tumor 2 Uveal Melanoma 2 Solid Tumors 2 Solid Tumor 2 Rhabdomyosarcoma 2

Interventions

enzalutamide 4 cabazitaxel 3 Docetaxel 3 Prednisone 2 talazoparib 1 rucaparib 1 pembrolizumab 1 olaparib 1 Zuclomiphene 1 XRP6258 1 Radiosurgery 1 Positron Emission Tomography Computed Tomography 1 LY3023414 1 Injections 1 Carboplatin 1 Abiraterone Acetate 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03434158 2022-11-03

IMANOL

Spanish Oncology Genito-Urinary Group

Phase 2 Completed

Prostate Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon ⚡